Biohaven Therapeutics discloses prodrugs of betahistine
March 19, 2026
Biohaven Therapeutics Ltd. has presented prodrugs of betahistine reported to be useful for the treatment of obsessive-compulsive disorder, trichotillomania, Tourette syndrome, amyotrophic lateral sclerosis, multiple sclerosis and more.